用单克隆抗体的附加组合疗法:对药物开发的影响
Jeffrey Cummings1, Aaron H Burstein2, Howard Fillit2
1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, Nevada, USA.
The journal of prevention of Alzheimer's disease
|October 27, 2025
概括
新型补充疗法对于早期阿尔茨海默病 (AD) 治疗与抗粉样蛋白单克隆抗体 (MABs) 一起至关重要. 谨慎的试验设计和生物标志物评估对于证明AD管理中的疗效和优化患者护理至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 三种抗粉样单克隆抗体 (MAB) 是FDA批准用于早期阿尔茨海默病 (AD).
- 这些MAB的使用越来越多,需要开发新的附加疗法.
- 对抗粉样蛋白剂的补充治疗有有限的经验.
研究的目的:
- 概述开发早期阿尔茨海默病的新增治疗方法的考虑因素.
- 强调试验设计和生物标志物评估在附加疗法研究中的重要性.
- 确保最佳的患者结果和联合治疗的临床实施.
主要方法:
- 审查当前的抗粉样蛋白MABs (aducanumab,lecanemab,donanemab) 和它们的特征.
- 讨论启动附加疗法的谨慎方法,包括时间和患者选择.
- 强调设计附加试验,使用特定的生物标志物策略,并考虑患者的便利性.
主要成果:
- 理想情况下,补充疗法试验应该集中在单一的MAB类型上,因为它们的机制和副作用概况不同.
- 证明临床益处需要证明除了单独使用抗粉胺MAB之外的疗效.
- 生物标志物分析,包括目标参与和新标志物,对于理解附加疗法影响至关重要.
结论:
- 补充疗法是管理AD复杂性的重要策略.
- 仔细考虑MAB类型,剂量,安全性和患者的便利性是成功实施附加疗法的关键.
- 综合的生物标志物评估将提供关键的洞察力,对新增的新增剂在AD的生物效应.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:31Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478